"Zidovudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
- AZT Antiviral
- 3' Azido 3' deoxythymidine
- AZT (Antiviral)
- 3' Azido 2',3' Dideoxythymidine
- AZT, Antiviral
- Antiviral AZT
Below are MeSH descriptors whose meaning is more general than "Zidovudine".
Below are MeSH descriptors whose meaning is more specific than "Zidovudine".
This graph shows the total number of publications written about "Zidovudine" by people in this website by year, and whether "Zidovudine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Zidovudine" by people in Profiles.
Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010 Aug; 54(4):381-8.
Jorgensen P, Marcus U, Albrecht H, Suttorp N, Schürmann D. Serial knife stabbings with HIV exposure--implications for post-exposure prophylaxis. J Infect. 2010 Jan; 60(1):76-8.
Chan SS, Santos JH, Meyer JN, Mandavilli BS, Cook DL, McCash CL, Kissling GE, Nyska A, Foley JF, van Houten B, Copeland WC, Walker VE, Witt KL, Bishop JB. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen. 2007 Apr-May; 48(3-4):190-200.
Cook JE, Dasgupta S, Middaugh LD, Terry EC, Gorry PR, Wesselingh SL, Tyor WR. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol. 2005 Jun; 57(6):795-803.
Muwakkit S, Locatelli F, Abboud M, Razzouk B, Wilimas J. Report of a child with vitiligo and Evans syndrome. J Pediatr Hematol Oncol. 2003 Apr; 25(4):344-5.
Harris NS, Thompson SJ, Ball R, Hussey J, Sy F. Zidovudine and perinatal human immunodeficiency virus type 1 transmission: a population-based approach. Pediatrics. 2002 Apr; 109(4):e60.
Kilby JM, Goepfert PA, Miller AP, Gnann JW, Sillers M, Saag MS, Bucy RP. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med. 2000 Sep 19; 133(6):435-8.
Biddle AK, Simpson KN. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine. Value Health. 2000 May-Jun; 3(3):186-201.
Mauskopf JA, Tolson JM, Simpson KN, Pham SV, Albright J. Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr. 2000 Apr 01; 23(4):302-13.
Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998 Jul; 4(7):1004-12.